Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Brokerages

Ocular Therapeutix, Inc. (NASDAQ:OCUL) has earned a consensus rating of “Moderate Buy” from the thirteen research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $22.5556.

A number of brokerages have recently weighed in on OCUL. Chardan Capital reaffirmed a “buy” rating and set a $21.00 price target on shares of Ocular Therapeutix in a report on Tuesday, December 9th. Royal Bank Of Canada restated an “outperform” rating on shares of Ocular Therapeutix in a research report on Wednesday, November 5th. Needham & Company LLC restated a “buy” rating and set a $20.00 target price on shares of Ocular Therapeutix in a research note on Monday, December 8th. Wall Street Zen lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, January 22nd.

Hedge Funds Weigh In On Ocular Therapeutix

Several large investors have recently bought and sold shares of OCUL. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Ocular Therapeutix by 17.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 893 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Ocular Therapeutix by 1.8% during the second quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company’s stock worth $674,000 after acquiring an additional 1,314 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Ocular Therapeutix by 62.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,392 shares during the last quarter. Trust Co. of Vermont lifted its stake in shares of Ocular Therapeutix by 24.3% in the fourth quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,750 shares during the period. Finally, Profund Advisors LLC boosted its holdings in Ocular Therapeutix by 9.9% in the third quarter. Profund Advisors LLC now owns 25,178 shares of the biopharmaceutical company’s stock valued at $294,000 after acquiring an additional 2,272 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock opened at $9.15 on Tuesday. The firm has a market cap of $1.95 billion, a PE ratio of -6.35 and a beta of 0.90. The company has a debt-to-equity ratio of 0.27, a current ratio of 7.85 and a quick ratio of 7.78. The stock’s fifty day moving average price is $12.08 and its two-hundred day moving average price is $12.01. Ocular Therapeutix has a one year low of $5.78 and a one year high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.02. The company had revenue of $14.54 million for the quarter, compared to analyst estimates of $14.57 million. Ocular Therapeutix had a negative return on equity of 86.33% and a negative net margin of 447.57%. As a group, research analysts expect that Ocular Therapeutix will post -0.98 EPS for the current fiscal year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.